Biological markers of bronchiolitis obliterans syndrome in recipients of allogeneic hematopoietic stem cell transplantation
https://doi.org/10.24884/1609-2201-2024-103-2-34-41
Abstract
Bronchiolitis obliterans syndrome (BOS) is a rare non-infectious pulmonary complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) or lung transplantation. Early diagnosis of BOS requires new approaches including the search for biological markers of pulmonary damage after allo-HSCT. The aim of this work is to review literary data on biological markers of BOS. Conclusion. Literary data on biomarkers of BOS in allo-HSCT recipients are limited. Further research is needed.
About the Authors
E. A. Kulagin
Pavlov University
Russian Federation
Russian Federation
Egor A. Kulagin, Cand. of Sci. (Med.), Assistant of Department of Hospital Therapy with a Course of Allergology and Immunology named after ac. M. V. Chernorutsky with clinic, pulmonologist, Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation
Saint Petersburg, 194044
V. I. Trofimov
Pavlov University
Russian Federation
Russian Federation
Vasiliy I. Trofimov, Dr. of Sci. (Med.), Professor, Honored Scientist of the Russian Federation, Department of Hospital Therapy with a Course of Allergology and Immunology named after ac. M. V. Chernorutsky with clinic
Saint Petersburg
References
1. A. G. Chuchalin, eds. Pulmonology. National guidelines. Moscow: GEOTAR-Media, 2020. 768 p. (In Russ.). ISBN 978-5-9704-5323-0.
2. Barker A. F., Bergeron A., Rom W. N., Hertz M. I. Obliterative bronchiolitis. N. Engl. J. Med. 2014;370(19):1820–1828. DOI: 10.1056/NEJMra1204664.
3. Kulagin E. A., Volkova A. G., Nikolaev I. Yu. et al. Incidence, risk factors and clinical characteristics of bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Pulmonologiya. 2022;32(1):77–88. (In Russ.). DOI: 10.18093/0869-0189-2022-32-1-77-88.
4. Filipovich A. H., Weisdorf D., Pavletic S. et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease): I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56. DOI: 10.1016/j.bbmt.2005.09.004.
5. Jagasia M. H., Greinix H. T., Arora M. et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401. DOI: 10.1016/j.bbmt.2014.12.001.
6. Kitko C. L., Pidala J., Schoemans H. M. et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transplant Cell Ther. 2021;27(7):545–557. DOI: 10.1016/j.jtct.2021.03.033.
7. Glanville A. R., Benden C., Bergeron A. et al. Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions. ERJ Open Res. 2022;8(3):00185–2022. DOI: 10.1183/23120541.00185-2022.
8. Bos S., Murray J., Marchetti M. et al. ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus- host disease in adults. Eur Respir J. 2024;63(3):2301727. DOI: 10.1183/13993003.01727-2023.
9. Boehler A., Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J. 2003;22(6):1007–18. DOI: 10.1183/09031936.03.00039103.
10. Cooke K. R., Luznik L., Sarantopoulos S. et al. The Biology of Chronic Graft-versus-Host Disease): A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017;23(2):211–234. DOI: 10.1016/j.bbmt.2016.09.023.
11. Zeiser R., Blazar B. R. Pathophysiology of Chronic Graft- versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017;377(26):2565–2579. DOI: 10.1056/NEJMra1703472.
12. Ghimire S., Weber D., Mavin E. et al. Pathophysiology of GvHD and Other HSCT-Related Major Complications. Front Immunol. 2017;8:79. DOI: 10.3389/fimmu.2017.00079.
13. Skvortsova Y. V., Novichkova G. A., Maschan A. A. New advances in pathogenesis, diagnostic and treatment of chronic graft-versus- host disease after allogeneic hematopoietic stem cell transplantation. Pediatric Hematology/Oncology and Immunopathology. 2018;17(2):121–135. (In Russ.). DOI: 10.24287/1726-1708-2018-17-2-121-135.
14. Williams K. M., Inamoto Y., Im A. et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplant Cell Ther. 2021;27(6):452–466. DOI: 10.1016/j.jtct.2021.02.035.
15. Wolff D., Greinix H., Lee S. J. et al. Biomarkers in chronic graft-versus-host disease: quo vadis? Bone Marrow Transplant. 2018;53(7):832–837. DOI: 10.1038/s41409-018-0092-x.
16. Mattsson J., Remberger M., Andersson O. et al. Decreased serum levels of clara cell secretory protein (CC16) are associated with bronchiolitis obliterans and may permit early diagnosis in patients after allogeneic stem-cell transplantation. Transplantation. 2005;79(10):1411–6. DOI: 10.1097/01.tp.0000158354.39635.ab.
17. Hermans C., Bernard A. Lung epithelium-specific proteins: characteristics and potential applications as markers. Am J Respir Crit Care Med. 1999;159(2):646–78. DOI: 10.1164/ajrccm.159.2.9806064.
18. Dierynck I., Bernard A., Roels H., De Ley M. Potent inhibition of both human interferon-gamma production and biologic activity by the Clara cell protein CC16. Am J Respir Cell Mol Biol. 1995;12(2):205–10. DOI: 10.1165/ajrcmb.12.2.7865218.
19. Lesur O., Bernard A., Arsalane K. et al. Clara cell protein (CC- 16) induces a phospholipase A2-mediated inhibition of fibroblast migration in vitro. Am J Respir Crit Care Med. 1995;152(1):290–7. DOI: 10.1164/ajrccm.152.1.7541278.
20. Nakane T., Nakamae H., Kamoi H. et al. Prognostic value of serum surfactant protein D level prior to transplant for the development of bronchiolitis obliterans syndrome and idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;42(1):43–9. DOI: 10.1038/bmt.2008.73.
21. Hartl D., Griese M. Surfactant protein D in human lung diseases. Eur J Clin Invest. 2006;36(6):423–35. DOI: 10.1111/j.1365-2362.2006.01648.x.
22. Zhang H., Chen L., Wu L. et al. Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2020;99(16):e19493. DOI: 10.1097/MD.0000000000019493.
23. Kuzmina Z., Greinix H. T., Weigl R. et al. Significant differences in B-cell subpopulations characterize patients with chronic graft- versus-host disease-associated dysgammaglobulinemia. Blood. 2011;117(7):2265–74. DOI: 10.1182/blood-2010-07-295766.
24. Carsetti R., Rosado M. M., Donnanno S. et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol. 2005;115(2):412–7. DOI: 10.1016/j.jaci.2004.10.048.
25. Kainulainen L., Varpula M., Liippo K. et al. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. JAllergy Clin Immunol. 1999;104(5):1031–6. DOI: 10.1016/s0091-6749(99)70085-0.
26. Kuzmina Z., Krenn K., Petkov V. et al. CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. Blood. 2013;121(10):1886– 95. DOI: 10.1182/blood-2012-06-435008.
27. Yamashita C. M., Dolgonos L., Zemans R. L. et al. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am J Pathol. 2011;179(4):1733–45. DOI: 10.1016/j.ajpath.2011.06.041.
28. Liu X., Yue Z., Yu J. et al. Proteomic Characterization Reveals That MMP-3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation. Am J Transplant. 2016;16(8):2342–51. DOI: 10.1111/ajt.13750.
29. Inamoto Y., Martin P. J., Onstad L. E. et al. Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021;27(9):759.e1–759.e8. DOI: 10.1016/j.jtct.2021.06.006.
30. Yu J., Storer B. E., Kushekhar K. et al. Biomarker Panel for Chronic Graft-Versus-Host Disease. J Clin Oncol. 2016;34(22):2583–90. DOI: 10.1200/JCO.2015.65.9615.
31. Rosewich M., Zissler U. M., Kheiri T. et al. Airway inflammation in children and adolescents with bronchiolitis obliterans. Cytokine. 2015;73(1):156–62. DOI: 10.1016/j.cyto.2014.10.026.
32. Koh Y. Y., Jung D. E., Koh J. Y. et al. Bronchoalveolar cellularity and interleukin-8 levels in measles bronchiolitis obliterans. Chest. 2007;131(5):1454–60. DOI: 10.1378/chest.06-0188.
33. Jerkic S. P., Michel F., Donath H. et al. Calprotectin as a New Sensitive Marker of Neutrophilic Inflammation in Patients with Bronchiolitis Obliterans. Mediators Inflamm. 2020;2020:4641585. DOI: 10.1155/2020/4641585.
34. Ostrin E. J, Rider N. L., Alousi A. M. et al. A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus- Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept. Immunohorizons. 2023;7(6):421– 430. DOI: 10.4049/immunohorizons.2300031.
35. Logan B. R., Fu D., Howard A. et al. Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death. J Clin Invest. 2023;133(15):e168575. DOI: 10.1172/JCI168575.
36. Groom J. R., Luster A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89(2):207–15. DOI: 10.1038/icb.2010.158.
37. Macheda M. L., Stacker S. A. Importance of Wnt signaling in the tumor stroma microenvironment. Curr Cancer Drug Targets. 2008;8(6):454–65. DOI: 10.2174/156800908785699324.
38. Federico G., Meister M., Mathow D. et al. Tubular Dickkopf-3 promotes the development of renal atrophy and fibrosis. JCI Insight. 2016;1(1):e84916. DOI: 10.1172/jci.insight.84916.
Review
For citations:
Kulagin E.A., Trofimov V.I. Biological markers of bronchiolitis obliterans syndrome in recipients of allogeneic hematopoietic stem cell transplantation. New St. Petersburg Medical Records. 2024;(2):34-41. (In Russ.) https://doi.org/10.24884/1609-2201-2024-103-2-34-41
Views:
78
Email this article 